Study wrapper · #1254
Increasing skeletal muscle mass and strength during incretin-based weight loss.
Editor's note
This speaks directly to the muscle-loss concern that shadows incretin-based weight loss, and the grip-strength gains are a functional outcome, not just a body-composition estimate. But the design limits are substantial: an uncontrolled, retrospective case series from one clinic, with muscle mass measured by bioelectrical impedance — a method with meaningful error, especially during rapid weight change. Testosterone therapy and structured resistance training are each capable of producing these gains on their own. Read this as a proof-of-concept that muscle can be protected during tirzepatide-driven weight loss under an intensive multimodal program, not as evidence about tirzepatide itself.
Plain-language abstract
A single clinic reviewed records of 93 men with obesity and low testosterone who received weekly tirzepatide alongside testosterone injections, resistance-exercise coaching, and dietary support. Over 12 months the men lost 18-20% of body weight — almost entirely fat — while estimated skeletal muscle mass rose 4-12% and grip strength climbed roughly 20%. Because everyone got all interventions at once and there was no comparison group, it is impossible to say which component drove the muscle gains.